Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-616 inhibitor
- Development stage
- Preclinical
- Lead developer
- The University of Hong Kong
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
01
Overview
miR-616 inhibitor refers to a class of experimental RNA-based agents, such as antisense oligonucleotides or shRNA, designed to antagonize the function of microRNA-616 (miR-616). miR-616 has been identified as an oncomiR that is significantly overexpressed in androgen-independent (castration-resistant) prostate cancer compared to androgen-dependent stages and benign tissues. It promotes tumor progression by directly targeting and suppressing the expression of the tumor suppressor Tissue Factor Pathway Inhibitor-2 (TFPI-2), which in turn stimulates cell proliferation and migration. Preclinical research, including studies using lentiviral-mediated knockdown, has demonstrated that inhibiting miR-616 can restore TFPI-2 levels, diminish cancer cell proliferation in vitro, and repress tumor growth in vivo. These findings suggest that miR-616 is a potential therapeutic target for preventing or treating the progression of prostate cancer to its more aggressive, treatment-resistant forms.
- Other names
- microRNA-616 inhibitormicroRNA616 inhibitormicroRNA 616 inhibitoranti-miR-616anti-miR616anti-miR 616miR-616 knockdownmiR616 knockdownmiR 616 knockdown
Beyond the preview
Go deeper on miR-616 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-616 inhibitor.